
Sign up to save your podcasts
Or


As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.

78,730 Listeners

32,255 Listeners

6,997 Listeners

28,977 Listeners

16,315 Listeners

2,679 Listeners

408 Listeners

2,173 Listeners

1,992 Listeners

437 Listeners

12,119 Listeners

17,589 Listeners

971 Listeners

113,520 Listeners

196 Listeners

30 Listeners

10,241 Listeners

4 Listeners

58 Listeners

233 Listeners

228 Listeners

69 Listeners

81 Listeners

86 Listeners

398 Listeners

21 Listeners

12 Listeners

8 Listeners

2 Listeners

123 Listeners

1,172 Listeners

184 Listeners